Kardigan

Precision cardiovascular therapeutics

KARD · Nasdaq · United States

Share price · KARD

$12.32-8.60 (-41.11%) 3M

close as of 2026-11-18 · 24h delayed · vol 546K (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when KARD's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 6 Nov 2026+12.0%
  2. 6 Oct 2026-11.5%
  3. 2 Sep 2026+11.8%

    Nothing announced by KARD that day or the session before.

Share of unusual movement by asset

For each asset, the share of KARD's own-move activity since 22 Jun 2026 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—14%
Sessions with no dated event—86%

No dated announcements about its assets since 22 Jun 2026.

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
Cardiac myosin (activator)Small molecule
Heart Failure
Phase 2
Angiotensinogen (AGT)RNA / oligonucleotide
Hypertension

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
TonlamarsenPhase 2Hypertension, Acute Severe Hypertension, Hypertensive Emergency, Hypertensive Urgency
Est. primary completion 2026-12 · NCT07511361 · CT.gov ↗
What to watch
2027 (1)
September 2027 (1)
DanicamtivPhase 2/3Symptomatic Genetic Dilated Cardiomyopathy
Est. primary completion 2027-09 · NCT07210723 · CT.gov ↗
What to watch
2032 (1)
November 2032 (1)
DanicamtivPhase 3Symptomatic Genetic Dilated Cardiomyopathy (DCM)
Est. primary completion 2032-11 · NCT07771465 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (5)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$64M$79M+ $393M short-term inv.$59M-$60M operating cash flowreport ↗
View 4 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$56M$385M+ $214M short-term inv.$116Mreport ↗
2026-Q1——$287M$56Mreport ↗
2025-Q3—$49M$170M$60M-$47M operating cash flowreport ↗
2025-Q2—$36M$91M$57Mreport ↗

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$153M—+ $227M short-term inv.$192Mreport ↗

Kardigan reported R&D spend of $153M and a quarterly net burn of $191.9M for fiscal year 2025.

Figures only: this period's report disclosed no narrative text

View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY——$50M—report ↗

Insider transactions

Open-market activity, trailing 12 months: 3 purchases ($90.0M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-29Reinke Kristin Marie K · directorAward / grant (derivative)48,368——Form 4
2026-06-22ARCH Venture Partners XIII, LLC; ARCH Venture Partners XIII, L.P.; ARCH Venture Fund XIII, L.P.; CRANDELL KEITH; NELSEN ROBERT; Burow Kristina; GILLIS STEVEN · director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% ownerOpen-market purchase1,250,000$16.00$20.0MForm 4
2026-06-22BERNS PAUL L · director, 10% ownerOpen-market purchase1,250,000$16.00$20.0MForm 4
2026-06-22HRTG GPE, LLC; HRTG PV, L.P.; HRTG CIF 2024, L.P.; Kelly Kevin Anthony; Johnson Keith Bryon · 10% owner; 10% owner; 10% owner; 10% owner; 10% ownerOpen-market purchase3,125,000$16.00$50.0MForm 4
2026-06-17PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; Perceptive Capital Solutions Holdings LP; EDELMAN JOSEPH · director; director; director; directorAward / grant20,706——Form 4
2026-06-17Edelberg Jay · Chief Medical OfficerConversion97,587——Form 4
2026-06-17Giordano Douglas E. · directorAward / grant20,706——Form 4
2026-06-17GIANAKAKOS ANASTASIOS · director, President & CEOConversion28,702——Form 4